Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | TSHR | P16473 | 6/20 | 0.72 |
| ▸ | HTT | P42858 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328130 | 0.97 | TSHR (0.68) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6324019 | 0.91 | MAPT (0.59) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6326044 | 0.89 | MAPT (0.56) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6334598 | 0.88 | LMNA (0.62) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6327914 | 0.88 | MAPT (0.56) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6331273 | 0.82 | MAPT (0.48) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6328013 | 0.81 | TSHR (0.57) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6324750 | 0.80 | TSHR (0.57) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6332641 | 0.78 | PARP1 (0.47) | MAPTTSHRHTTALDH1A1LMNA | |
| SCHEMBL6325218 | 0.78 | MAPT (0.53) | MAPTTSHRHTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939981-B1 | ruthenium complexes of phosphine-aminophosphine ligands are useful as catalyst for the asymmetric hydrogenation of beta -ketoesters to beta -hydroxyesters | EASTMAN CHEMICAL COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | MAPT 729/4885TSHR 4656/4885HTT 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.